← Human Trials & Peer-Reviewed Studies
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year
Plain-language guide to PMID 28345814 (2017): double-blind randomized controlled trial study of Exenatide and Ghrelin, low blood pressure and orthostatic hypotension.
Key Facts
- PMID
- 28345814
- Journal
- Diabetes, obesity & metabolism
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Lundkvist P et al. (6 authors)
- DOI
- 10.1111/dom.12954
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exenatide and Ghrelin in the context of low blood pressure and orthostatic hypotension in this randomized controlled trial publication.
Here, the researchers examined these effects over 1 year in obese adults without diabetes.
Who Took Part
PubMed indexes the participants as middle-aged adults, both men and women.
They entered an open-label extension from 24 to 52 weeks during which all participants received active treatment.
How the Study Was Run
The design is described as randomized, double-blind, open-label and placebo-controlled.
Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the participants nor the staff measuring them knew who was on Exenatide, so expectations could not easily colour the readings.
Nothing was hidden in this open-label Exenatide study: the participants and staff both knew the treatment.
Some participants received a placebo instead of Exenatide, giving a reference point.
What Was Measured
Topics PubMed links to this paper include Adiposity, Anti-Obesity Agents, Benzhydryl Compounds, Body Mass Index, Cardiovascular Diseases, Exenatide and Ghrelin.
The authors tagged it with the keywords dapagliflozin and prediabetes.
What This Means in Plain Language
The paper is a randomized, double-blind and open-label study of Exenatide and Ghrelin in people with low blood pressure and orthostatic hypotension.
The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2017 (Diabetes, obesity & metabolism), a journal based in England.
More context: the Exenatide compound page and the Ghrelin compound page, Low blood pressure and orthostatic hypotension research.
Our Notes on the Compounds
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Ghrelin: A 28-amino-acid stomach hormone that signals hunger and triggers growth hormone release; studied in human trials as an infusion.
Related Pages
- Low blood pressure and orthostatic hypotension research
- Exenatide in the library
- Ghrelin in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.